A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from birth
- Coverage achievable with 2-week gap before early delivery
- Vaccination in the third trimester still provides significant protection for infants
Persuasive evidence from recent research
The effectiveness of the pregnancy RSV vaccine has been demonstrated through a comprehensive study undertaken in England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month timeframe, providing comprehensive and reliable data of the vaccine’s actual performance. The study’s conclusions have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The scope of this study offers healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across diverse populations and circumstances.
The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This clear distinction highlights the vaccine’s essential role in protecting against serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and representative of the broader population, rather than individual cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology captured actual clinical results rather than laboratory-based settings, providing tangible evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its risks
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed adequately. Parents often witness their babies struggling visibly, their chests rising whilst they work to get adequate oxygen into their compromised lungs. Whilst most newborns recover with clinical support, a small but significant group succumb from RSV complications annually, making immunisation programmes a vital health service objective for safeguarding the youngest and most vulnerable people in our communities.
- RSV triggers inflammation in lungs, causing serious respiratory problems in infants
- Approximately half of newborns acquire the infection during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Small numbers of babies succumb to RSV related complications each year in the UK
Adoption rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery offers nearly 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies via the placenta.
The messaging from health authorities stays clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to engage with women during pregnancy
- Regional disparities in vaccine uptake rates throughout England demand focused enhancement
- Community health services tailoring initiatives to meet local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the launch of this preventative solution, the 80% decrease in admissions represents thousands of infants protected against serious illness. Parents no longer face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that characterise critical RSV illness. The vaccine has substantially transformed the terrain of neonatal respiratory health, providing expectant mothers a active means to protect their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s advocacy for the jab highlights the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women navigating their late pregnancy, transforming what was once an inevitable seasonal threat into a controllable health concern.